



Lieferantenvielfalt im E-Procurement-System – wenn die Produktion weiter laufen muss

Dr. Matthias Kuschel, Teva Deutschland



Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

- our generics medicines business, including: that we are substantially more dependent on this business, with its significant attendant risks, following our acquisition of Allergan plc's worldwide generic pharmaceuticals business; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our generic products, both from competing products and increased regulation; delays in launches of new generic products; our ability to take advantage of high-value biosimilar opportunities; efforts of pharmaceutical companies to limit the use of generics including through legislation and regulations; the difficulty and expense of obtaining licenses to proprietary technologies; returns, allowances and chargebacks; and investigations of the calculation of wholesale prices;
- our specialty medicines business, including: competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; our ability to achieve expected results from investments in our product pipeline; competition from companies with greater resources and capabilities; and the effectiveness of our patents and other measures to protect our intellectual property rights;
- our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
- our business and operations in general, including: failure to effectively execute the recently announced restructuring plan; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline of future products due to the expected review of our R&D programs; our ability to develop and commercialize additional pharmaceutical products; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers in our U.S. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
- compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
- other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2017, including in the section captioned "Risk Factors," and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

-
- 1 Teva in Germany
 - 2 The role of Indirect Procurement for production
 - 3 Conclusion

ONE Teva

Facts and figures

- German headquarters in Ulm
- Around 2,500 employees
- Innovative specialty medicines, generics and OTC medications under the Teva umbrella
- Every day in Germany, one in eight prescriptions is a medicine produced by Teva
- Plant for the production of biopharmaceutical medications in Ulm
- Pharmaceutical manufacturing in Ulm and Blaubeuren/Weiler
- Largest production facility for preservative-free nasal sprays in Europe

Top 15 corporate groups in the German pharmaceutical market

TOP15 Konzerne im deutschen Pharma Markt (Retail + Hospital inkl. PI) nach Euro Umsatz in Mio. - **Jahr 2018**


Quelle: Insight Health Retail Sell-Out + IQVIA DKM (Hospital hmol) - BA Portal - DatenStand 12/2018

Konzern inkl. PI	Jahr 2016	Jahr 2017	Jahr 2018	Marktanteil	Trend in %
Total Pharma Markt	41.082	42.631	45.288		6,2%
① Novartis	3.769,3	3.872,3	4.295,1	9,5%	10,9%
② Hoffmann-La Roche	2.604,1	2.467,3	2.460,9	5,4%	-0,3%
③ Sanofi	1.940,8	1.912,2	1.992,2	4,4%	4,2%
④ Johnson & Johnson	1.299,1	1.526,1	1.863,8	4,1%	22,1%
⑤ Merck Sharp & Dohme	1.704,5	1.762,6	1.803,4	4,0%	2,3%
⑥ Bayer	1.673,8	1.690,0	1.743,9	3,9%	3,2%
⑦ TEVA	1.495,4	1.553,9	1.525,7	3,4%	-1,8%
⑧ Abbott	1.158,6	1.222,7	1.312,3	2,9%	7,3%
⑨ Biogen	743,2	1.023,5	1.248,9	2,8%	22,0%
⑩ Pfizer	1.191,5	1.302,1	1.244,3	2,7%	-4,4%
⑪ Glaxo SmithKline	1.185,0	1.210,0	1.239,0	2,7%	2,4%
⑫ Bristol-Myers Squibb	628,9	710,3	853,9	1,9%	20,2%
⑬ Stada AG	827,8	802,8	802,2	1,8%	-0,1%
⑭ Celgene	524,4	608,0	783,4	1,7%	28,9%
⑮ Lilly	675,2	700,3	779,5	1,7%	11,3%

The ratiopharm medicines brand

ratiopharm

Gute Preise. Gute Besserung.



The epitome of top-quality medicines at an affordable price for more than 40 years


Almost all areas of illness covered: One of the largest and most extensive portfolios of preparations

Over 25 million units per year: ratiopharm nasal spray the best-selling medication in the over-the-counter pharmacy market


Pharma production under Covid-19



Low value items can be key



Both long-standing relationships and new suppliers are needed



Thank you very much.

